Exodus Point Capital Management, LP Beam Therapeutics Inc. Transaction History

Exodus Point Capital Management, LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	SELL	$23.46 - $45.07 $593,678 - $1.14 Million	-25,306 Reduced 74.91%	8,475 $280,000
Q3 2023 Nov 09, 2023	BUY	$23.01 - $32.46 $777,300 - $1.1 Million	33,781 New	33,781 $812,000
Q2 2022 Aug 19, 2022	SELL	$29.86 - $62.36 $760,623 - $1.59 Million	-25,473 Closed	0 $0
Q1 2022 May 13, 2022	BUY	$53.73 - $82.16 $786,069 - $1.2 Million	14,630 Added 134.93%	25,473 $1.46 Million
Q4 2021 Feb 11, 2022	BUY	$68.02 - $99.06 $737,540 - $1.07 Million	10,843 New	10,843 $864,000
Q1 2021 May 17, 2021	SELL	$71.28 - $120.75 $1.08 Million - $1.82 Million	-15,108 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$22.24 - $95.63 $336,001 - $1.44 Million	15,108 New	15,108 $1.23 Million

236

75.2M

438K

232K

Ticker BEAM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,354,600
Market Cap $1.78B
Description
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen ...

Get notified when there are updates to the investment portfolio of Exodus Point Capital Management, LP, based on Form 13F filings with the SEC.

Stay updated on Exodus Point Capital Management, LP with notifications on news.